Diffuse Cutaneous Systemic Sclerosis
📧 Sign up to get email alerts when something new happens for Diffuse Cutaneous Systemic Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc) [Phase 2]
A Phase 2 clinical trial update for MTX-474 in participants with diffuse cutaneous systemic sclerosis (dcSSc) shows the study is currently r…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Controlling Hyperactive Immunity With Long-lived Lymphocytes [Phase 1, Phase 2]
Quell Therapeutics is running Phase 1/2 trials to control hyperactive immunity with long-lived lymphocytes, enrolling participants with diff…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension [Phase 2]
An update on a Phase 2 trial of oral Ifetroban for diffuse cutaneous systemic sclerosis and SSc-associated pulmonary arterial hypertension, …
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis [Phase 2]
This entry reports a Phase 2 clinical trial evaluating the combination of belimumab and rituximab for diffuse cutaneous systemic sclerosis, …
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis [Phase 2]
A Phase 2 clinical study is evaluating ianalumab in participants with diffuse cutaneous systemic sclerosis, sponsored by Novartis, and curre…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis [Phase 2]
Clinical trial update for a Phase 2 study evaluating rapcabtagene autoleucel in participants with diffuse cutaneous systemic sclerosis.
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 [Phase 1]
Phase 1 study update for KYV-101 (CARTIMMUNE) evaluating autoimmune diseases including idiopathic inflammatory myopathies, diffuse cutaneous…
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Diffuse Cutaneous Scleroderma (DSSc) SFDI Study [NA]
This clinical trial update notes that the Diffuse Cutaneous Scleroderma SFDI study (NCT07090226) sponsored by Boston University is currently…
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases [Phase 1]
Century Therapeutics’ CNTY-101 is being evaluated in a Phase 1 study for refractory B cell–mediated autoimmune diseases, with the trial curr…
-
CLINICAL_TRIALS research · 2025-10-20Clinical Trial Update: Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) [Phase 2]
Phase 2 safety and efficacy trial of tulisokibart (MK-7240/PRA023) for diffuse cutaneous systemic sclerosis-associated interstitial lung dis…
-
CLINICAL_TRIALS research · 2025-10-08Clinical Trial Update: KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis [Phase 1, Phase 2]
This document provides an update on KYSA-5, Kyverna Therapeutics' CD19 CAR T-cell trial for systemic sclerosis, indicating the study remains…
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: Patients Diagnosed With Scleroderma: Physical Performance and Functionality
Clinical trial update for NCT07183072 indicating ongoing recruitment at Hacettepe University to assess physical performance and functionalit…
-
CLINICAL_TRIALS research · 2025-06-11Clinical Trial Update: Pathogenic Mechanisms Involved in the Initiation and Progression of Systemic Sclerosis [NA]
A clinical trial update examining pathogenic mechanisms involved in the initiation and progression of systemic sclerosis. It is currently no…
-
CLINICAL_TRIALS research · 2025-04-20Clinical Trial Update: Safety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate [Phase 3]
Phase 3 clinical trial evaluating safety and efficacy of baricitinib for skin tightening in diffuse cutaneous systemic sclerosis, compared w…
-
CLINICAL_TRIALS research · 2025-03-13Clinical Trial Update: Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis [Phase 2]
Phase 2 clinical trial evaluating Extracorporeal Photopheresis for early diffuse cutaneous systemic sclerosis; the study is not yet recruiti…
-
CLINICAL_TRIALS research · 2025-02-11Clinical Trial Update: Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis [Phase 2]
A Phase 2 clinical trial is investigating the efficacy and safety of Telitacicept for systemic sclerosis, focusing on the diffuse cutaneous …
-
CLINICAL_TRIALS research · 2024-12-04Clinical Trial Update: Phenotyping of Chronic Pain in Diffused Systemic Scleroderma [NA]
A clinical trial investigating chronic pain phenotypes in diffuse cutaneous systemic sclerosis has completed.
-
CLINICAL_TRIALS research · 2024-11-27Clinical Trial Update: US Zamto-cel Autoimmune Diseases [Phase 1]
Miltenyi Biomedicine reports a Phase 1 trial of Zamto-cel for autoimmune diseases including lupus nephritis, systemic lupus erythematosus, s…
-
CLINICAL_TRIALS research · 2024-11-18Clinical Trial Update: Open Label Extension Study of Brentuximab Vedotin in Early dcSSc [Phase 2]
Open-label extension study of Brentuximab Vedotin for early diffuse cutaneous systemic sclerosis; Phase 2, currently recruiting.
-
CLINICAL_TRIALS research · 2011-08-18Clinical Trial Update: AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis [Phase 2]
Phase 2 clinical trial update for AIMSPRO in established diffuse cutaneous systemic sclerosis (systemic sclerosis).